AC Immune SA
ACIU
$2.28
-$0.09-3.80%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.72M | -- | -- | -- | 1.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.72M | -- | -- | -- | 1.00K |
| Cost of Revenue | 16.54M | 14.05M | 15.22M | 14.99M | 15.73M |
| Gross Profit | 177.30K | -14.05M | -15.22M | -14.99M | -15.72M |
| SG&A Expenses | 4.58M | 3.92M | 4.10M | 4.44M | 4.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -400.90K | -459.70K | -352.70K | -440.90K | -414.50K |
| Total Operating Expenses | 20.71M | 17.51M | 18.96M | 18.99M | 19.43M |
| Operating Income | -4.00M | -17.51M | -18.96M | -18.99M | -19.43M |
| Income Before Tax | -5.36M | -17.14M | -18.72M | -18.92M | -19.48M |
| Income Tax Expenses | 1.10K | 3.40K | 3.30K | 3.20K | 2.10K |
| Earnings from Continuing Operations | -5.36M | -17.15M | -18.73M | -18.93M | -19.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.36M | -17.15M | -18.73M | -18.93M | -19.48M |
| EBIT | -4.00M | -17.51M | -18.96M | -18.99M | -19.43M |
| EBITDA | -3.53M | -17.04M | -18.51M | -18.52M | -18.95M |
| EPS Basic | -0.06 | -0.20 | -0.22 | -0.23 | -0.23 |
| Normalized Basic EPS | -0.04 | -0.13 | -0.14 | -0.14 | -0.15 |
| EPS Diluted | -0.06 | -0.20 | -0.22 | -0.23 | -0.23 |
| Normalized Diluted EPS | -0.04 | -0.13 | -0.14 | -0.14 | -0.15 |
| Average Basic Shares Outstanding | 86.74M | 84.72M | 84.61M | 83.63M | 83.60M |
| Average Diluted Shares Outstanding | 86.74M | 84.72M | 84.61M | 83.63M | 83.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
